ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
27 announcements with these filters
Neochem Bio Solutions Limited held its 9th Annual General Meeting on September 21, 2026, where management reviewed the company's performance and discussed future business strategies.
Promoter Swapnil R. Makati acquired 1,200 equity shares of Neochem Bio Solutions Limited for ₹0.14 Crore via an on-market purchase.
Promoter and MD Swapnil Makati purchased 7,200 Neochem Bio Solutions shares on NSE for ₹0.07 Crore. His stake rose from 54.70% to 54.74%.
Neochem Bio Solutions Limited has appointed Mr. Siddharth Raj as Business Head (Textiles) Corporate Accounts. This Senior Management Personnel appointment is effective August 29, 2026.
Neochem Bio Solutions Limited has re-appointed M.K. Chokshi & Associates as Secretarial Auditor and Mrunal M. Shah & Co. as Internal Auditor for specified terms.
Neochem Bio Solutions Limited has scheduled its 9th Annual General Meeting for September 21, 2026, via video conferencing. The Board also approved the annual report.
Mr. Hitesh Wadher has resigned as Vice President - Marketing and Senior Management Personnel of Neochem Bio Solutions Limited, effective August 31, 2026.
Neochem Bio Solutions Limited has scheduled a board meeting for August 24, 2026, to discuss other business matters. No further details on the agenda were provided.
Promoter Swapnil Rameshbhai Makati purchased 7,200 shares of Neochem Bio Solutions for ₹0.06 Crore on the open market.
Promoter Swapnil R. Makati purchased 6,000 equity shares of Neochem Bio Solutions Limited for Rs. 5.14 Lakhs. This on-market acquisition increases his stake by 0.035%.
Neochem Bio Solutions has provided an update on its cyber fraud incident, reporting that ₹0.75 Crore has been successfully traced and frozen in beneficiary accounts.
Neochem Bio Solutions reported a cyber fraud incident involving unauthorized payments of ₹1.50 Crore. The company has initiated legal action and strengthened its payment protocols.
Neochem Bio Solutions reported FY26 revenue of ₹110.7 Cr (+32% YoY) and PAT of ₹12.0 Cr (+62% YoY), driven by specialty chemical demand and segment diversification into home and personal care.
Neochem Bio Solutions corrected its financial results filing after an exchange query. It rectified XBRL-PDF mismatches and submitted the missing Working Capital Certificate.
Neochem Bio Solutions delivered strong FY26 results with 32% revenue growth and 53% EBITDA growth, driven by a shift to own-brand performance chemicals and expansion into HPC and paints.
Neochem Bio Solutions delivered a strong FY26 with 32% revenue growth and 53% EBITDA expansion, driven by a strategic pivot from white-label manufacturing to its own higher-margin specialty brand.
Neochem Bio Solutions Limited reported FY26 Total Income of ₹113.4cr, reflecting 32% YoY growth. Strategy focuses on diversifying from textile into HPC and industrial specialty chemicals.
Neochem Bio Solutions Limited confirmed full utilization of ₹44.97 Crore IPO proceeds with no deviations. Funds supported working capital, debt repayment, and general corporate purposes as per prospectus.
Neochem Bio Solutions Ltd reported revenue from operations of ₹64.9 Cr (+37.5% YoY) and net profit of ₹6.9 Cr (+25.5% YoY) for H2 FY26.
Neochem Bio Solutions reported FY26 revenue of ₹110.7 Crore, a 32% increase. Profit after tax rose 62% to ₹12.03 Crore, reflecting strong annual growth.
Neochem Bio Solutions Limited submitted its monitoring report confirming full utilization of ₹44.97 Crore IPO proceeds. No deviations were reported across various corporate objects.
Neochem Bio Solutions Limited will hold a board meeting on May 18, 2026, to consider audited financial results. The trading window remains closed until May 20, 2026.
Neochem Bio Solutions Limited announced the outcomes of its board meeting held on May 2, 2026. The board approved the appointments of M/s. Mrunal M. Shah & Co. as Internal Auditor and M/s. M.K Chokshi & Associates as Secretarial Auditor for the 2025-2026 financial year, ensuring compliance with SEBI regulatory requirements.
Neochem Bio Solutions Limited submitted its Structured Digital Database (SDD) compliance certificate for the quarter ended March 31, 2026. The certificate confirms the company maintained a non-tamperable database of UPSI events as required by SEBI (Prohibition of Insider Trading) Regulations.
Neochem Bio Solutions Limited has informed the exchange that it is not identified as a 'large corporate' for the financial year 2025-26 under SEBI guidelines. Consequently, the company is exempt from the specific disclosure requirements mandated for large corporates regarding fund raising through debt securities.
Neochem Bio Solutions Limited informed the exchange that the requirement to submit a quarterly Corporate Governance Report is not applicable to the company. This exemption is due to its listing on the NSE EMERGE SME platform and falling below specified regulatory thresholds for paid-up capital and net worth.
Neochem Bio Solutions Limited submitted its quarterly investor grievance report for the period ended March 31, 2026. One complaint was received during the quarter, and one remains unresolved at the end of the period. This periodic compliance disclosure provides transparency regarding the company's shareholder grievance redressal status.